Ionis Pharmaceuticals - Biotech company surprises with positive study data on Olezarsen

Business Driver: The US biotech company Ionis Pharmaceuticals (IONS) specializes in the development of drugs and therapies for the treatment of rare genetic diseases. With Spiranza (spinal muscular atrophy (SMA)), Tegsedi (hereditary transthyretin amyloidosis (hATTR)), and Waylivra (familial chylomicronemia syndrome (FCS)), Ionis has several promising candidates in advanced stages of clinical development. The hopes are particularly focused on Olezarsen, a drug that has shown promise in the treatment of familial chylomicronemia syndrome, a rare and...